|
C14ORF104 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.06119999962762E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.4319000000439E-06 |
| Normal-vs-Stage2 |
4.55539999999477E-06 |
| Normal-vs-Stage3 |
1.29739999965572E-07 |
| Normal-vs-Stage4 |
8.86009998701809E-09 |
| Stage1-vs-Stage2 |
6.662600E-01 |
| Stage1-vs-Stage3 |
1.013450E-01 |
| Stage1-vs-Stage4 |
3.596000E-03 |
| Stage2-vs-Stage3 |
4.358400E-01 |
| Stage2-vs-Stage4 |
7.802200E-02 |
| Stage3-vs-Stage4 |
2.632000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.91419999967724E-07 |
| Normal-vs-AfricanAmerican |
1.135980E-03 |
| Normal-vs-Asian |
2.21950000001137E-06 |
| Caucasian-vs-AfricanAmerican |
3.451600E-01 |
| Caucasian-vs-Asian |
9.823400E-01 |
| AfricanAmerican-vs-Asian |
3.711600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.56119999986204E-07 |
| Normal-vs-Female |
6.71110000016739E-07 |
| Male-vs-Female |
4.259000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.25529999994711E-06 |
| Normal-vs-Age(41-60Yrs) |
4.23629999968256E-07 |
| Normal-vs-Age(61-80Yrs) |
3.98069999962836E-07 |
| Normal-vs-Age(81-100Yrs) |
3.645800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.902000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.233400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.509600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.842000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.029200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.187200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.478700E-03 |
| Classical-VS-Follicular |
8.259400E-01 |
| Classical-VS-Other |
5.693200E-01 |
| Classical-VS-Normal |
2.6938999999615E-06 |
| Tall-VS-Follicular |
7.328500E-02 |
| Tall-VS-Other |
2.851800E-01 |
| Tall-VS-Normal |
3.0830999975251E-08 |
| Follicular-VS-Other |
6.554800E-01 |
| Follicular-VS-Normal |
4.25670000003819E-06 |
| Other-VS-Normal |
1.220640E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.46639999984733E-07 |
| Normal-vs-N1 |
2.9460999972919E-08 |
| N0-vs-N1 |
1.263030E-01 |
|
|
